Vaccination News Home Page subscribe Vaccination NewsLetter
http://www.journals.uchicago.edu/JID/journal/issues/v187nS1/020454/brief/020454.abstract.html
The Journal of Infectious Diseases 2003;187:S177-S185
© World Health Organization 2003. All rights reserved. The World Health
Organization has granted the Publisher permission for the reproduction of this
article.
0022-1899/2003/18710S-0028
Go to full text | Return to Issue Table of Contents
| SUPPLEMENT ARTICLE |
Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial
Kathryn A. Kohler,1 Ali Jaffer M. Suleiman,3 Susan E. Robertson,5 Pradeep Malankar,3 Saleh Al-Khusaiby,4 Rita F. Helfand,2 David Brown,6 William J. Bellini,2 and Roland W. Sutter1,a
1Global
Immunization Division, National Immunization
Program, and 2Division of
Viral and Rickettsial Diseases,
National Center for Infectious
Diseases, Centers for Disease
Control and Prevention, Atlanta,
Georgia; 3Ministry of Health and
4Royal Hospital, Muscat, Oman; 5Department
of Vaccines and Biologicals,
World Health Organization, Geneva,
Switzerland; 6Enteric, Respiratory and
Neurological Virus Laboratory, Central
Public Health Laboratory, London,
United Kingdom
| A prospective immunogenicity trial of measles and
rubella vaccines was conducted in Oman. Children
received measles vaccine at age 9 months and
measles-rubella vaccine at age 15 months.
Serum specimens were tested for measles-specific IgG
and rubella-specific IgG. Of 1025 eligible infants,
881 (86.0%) returned for all five visits and
had adequate serum samples for testing.
Seroconversion to measles after vaccination at 9
months was 98.1%. At 15 months, 47 (5.3%)
of the 881 children were seronegative for measles;
of these, 44 (93.6%) seroconverted. At 16 months,
99% of the children seronegative at age 9
months seroconverted after receiving two doses of
measles vaccine. At age 15 months, 684 (77.6%)
children were seronegative for rubella. Of
these, 676 (98.8%) seroconverted by age 16
months. One dose of measles vaccine at age 9
months was highly immunogenic. One dose of
measles-rubella vaccine at age 15 months closed the
remaining measles immunogenicity gap and resulted
in a high rate of rubella seroconversion.
|
The study protocols for phase I and phase
II of this clinical trial were approved by the
National Maternal Child Health Committee, Ministry of
Health, Oman; the Institutional Review Board, Centers for
Disease Control and Prevention, Atlanta; and the Secretariat
Committee for Research Involving Human Subjects, World Health
Organization, Geneva. Witnessed oral parental consent was
obtained for each study subject; consent was obtained
separately for phase I and phase II of the
study.
Financial support: Department of Vaccines and Biologicals, World
Health Organization (Geneva). SmithKline Beecham (Rixensart,
Belgium) provided the study vaccines free of charge.
a Present affiliation:
Vaccine Assessment and Monitoring, Department of Vaccines
and Biologicals, World Health Organization, Geneva,
Switzerland.
Go to full text | Return to Issue Table of Contents
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.